SGLT

YM543 free base is a potent, orally active inhibitor of the sodium-glucose cotransporter 2 (SGLT2). This compound effectively lowers blood glucose levels, making it a valuable tool in diabetes research. Its mechanism of action provides insights into glucose homeostasis and offers potential therapeutic strategies for managing diabetic conditions.

TP0438836 is a selective inhibitor of the sodium-glucose cotransporter 1 (SGLT1), demonstrating an IC50 value of 28 nM for human SGLT1 and 7 nM for human SGLT2. This compound is of significant interest in diabetes research, as it may help elucidate the role of glucose absorption in glucose homeostasis and insulin regulation. TP0438836 can be utilized in studies aimed at developing therapeutic strategies for managing diabetes and related metabolic disorders.

Sergliflozin-A is a selective inhibitor of sodium-glucose co-transporter proteins SGLT1 and SGLT2, which play key roles in glucose reabsorption in the kidney. By competitively inhibiting these transporters, Sergliflozin-A contributes to reduced glucose reabsorption, making it a valuable compound in the study and treatment of type 2 diabetes. Its efficacy may vary with different mutations in target sites, underscoring its potential for tailored therapeutic applications in metabolic disorders.

Galacto-Dapagliflozin is a selective inhibitor of the human sodium-glucose cotransporter 2 (hSGLT2), exhibiting a Ki value of 25 nM. This compound demonstrates significant potential in modulating glucose homeostasis and promoting renal glucose excretion. Its application extends to research in metabolic disorders, particularly in the study of type 2 diabetes and related glucose regulation mechanisms.

Fluoro-Dapagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, exhibiting a Ki value of 5.3 nM for SGLT2 and 330 nM for SGLT1. It functions by blocking glucose transport, thereby reducing glucose absorption in the kidneys. This compound is valuable for research applications aimed at understanding glucose homeostasis, diabetic metabolism, and the therapeutic potential in managing type 2 diabetes.